Table 1.
Shows some details of studies examining EPA/DHA in heart failure.
| Study | Country | Study Design |
%Male | Sample Size | Follow-Up | Age * | Dose EPA/DHA | Dose EPA | Dose DHA |
|---|---|---|---|---|---|---|---|---|---|
| Radaelli et al. 2006 | Italy | RCT | 96% | 15 | - | 59.4 (2.5) | 2 g daily n3-PUFA | - | - |
| Nodari et al. 2008. | Italy | RCT | 95.4% | 22 | 6 months | 61.09 ± 11.22 | 850 to 882 mg of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] ethyl esters in the average ratio EPA/DHA of 0.9:1.5 | - | - |
| Zhao et al. 2009 | China | RCT | 71% | 38 | 3 months | 74 (68,80) | 2 g/day of n-3 PUFA | - | - |
| Moertl et al. 2011 | Austria | RCT | 100% | 13 | 3 months | 61.9 ± 9.6 | 1 g/d omega-3-polyunsaturated fatty acids (n3-PUFAs) | - | - |
| Jiang et al. 2011 | USA | Prospective Cohort Study | 57.5% | 109 | N/A | 62 (55, 71) | - | - | - |
| Nodari et al. 2011 | Italy | RCT | 95.5% | 64 | 3 months | 61 (11.1) | 850 to 882 mg of EPA and DHA ethyl esters | - | - |
| Mozafferian et al. 2012 | USA | Prospective Cohort Study | - | 2735 | 14 years | - | - | - | - |
| Hara et al. 2013 | Germany | Retrospective cohort study | - | 712 | 1079 days | 65 (57–73) | - | - | - |
| Kojuri et al. 2013 | Iran | RCT | 58 | 38 | 1 Year | 54 | 2 g/day of omega 3 | - | - |
| Kohashi et al. 2014 | Japan | Prospective Cohort Study | - | 139 | 12 months | 70.2 ± 9.0 | - | 1800 mg daily | |
| Ghio et al. 2014 | Italy | RCT | 88.8% | 312 | 3 years | 67 (11) | 1:1 to n-3 PUFA (1 g/day) | - | - |
| Chrysohoou et al. 2016 | Greece | RCT | 79.2% | 101 | 6 months | 63 (12.8) | 1000 mg omega 3-PUFA supplementation | - | - |
| Ouchi et al. 2017 | Japan | Prospective Cohort Study | 68.3% | 306 | 2.4 ± 1.2 years | 66.4 ± 15.0 | - | - | - |
| Block et al. 2019 | USA | Prospective Cohort Study | 58.9% | 292 | 13 years | 69± 9 | - | - | - |
| Matsuo et al. 2021 | Japan | Retrospective Cohort Study | 42.9% | 140 | - | 84 (77–88) | - | - | - |
| Selvaraj et al. 2022 | USA | RCT | 69.3% | 1446 | - | 63.0 | - | - | - |
| Le et al. 2023 | USA | Prospective Cohort Study | 57% | 987 | 10 years | 61.5 ± 12.2 | - | - | - |